Rising dominance of Indian pharma companies

The market share of Indian pharma companies has increased to 42 per cent during Q2FY13.

 

Mumbai, December 2, 2012: Riding on the back of the increased revenue from the domestic market and the new product launches, the Indian pharma market has continued its strong performance. It is worth noting there that the domestic market contribution of Indian pharma companies has increased from 30 per cent to 32 per cent in the second quarter of FY 2012-13, as per a recent report from Barclays Equity Research.

 

The contribution of the Indian pharma companies is pegged at Rs 15,395 crore at the end of the second quarter of FY 2012-13. As per the report, names like Glenmark, Cadila and Lupin are the clear outperformers in the Indian market.

 

The report also mentioned that the operating margins of the Indian pharma companies continued to improve both sequentially and on a year-on-year basis. The rising dominance of the Indian pharma companies is a clear indicator towards the steady operating fundamentals of the Indian pharmaceutical industry.

 

Comment!
 
 






* Indicates mandatory field.
Please wait while comments are being sent...